The Global Coalition on Aging Applauds FDA for New Draft Alzheimer’s Guidance

New guidance provides clarity on endpoints, will help spur pharmaceutical innovation for Alzheimer’s treatments

NEW YORK, NY (17 May 2018) – The Global Coalition on Aging (GCOA) today submitted comments to the U.S. Food & Drug Administration (FDA) supporting the administration’s new regulatory guidance document on early Alzheimer’s disease and calling for similar updates for related dementias. The draft guidance clarifies the clinical endpoints required for early Alzheimer’s disease treatments, reflecting the latest understanding of the disease’s progression, and opening opportunities for increased pharmaceutical innovation.

“By issuing this new draft guidance, the FDA has demonstrated its commitment to rapidly advancing innovation in Alzheimer’s drug development,” said Michael Hodin, CEO of the Global Coalition on Aging. “As Alzheimer’s affects more and more of us across society as the population ages, researchers and regulators alike must adapt based on what the science has taught us. We applaud the FDA for its leadership in recognizing the urgency to update regulations and create a path for faster and smarter processes that remove barriers to innovation.”

GCOA is also calling for the FDA to make advancements in clinical trial enrollment: first, by developing common diagnostic criteria for enrollment in clinical trials. Secondly, GCOA is recommending more aggressive focus on earlier detection and diagnosis to help ensure adequate participation from people with Alzheimer’s in clinical trials. By collecting data earlier in the progression of dementia, researchers can pinpoint drug targets more effectively and efficiently.

GCOA’s comments are in line with findings from the Dementia Innovation Readiness Index,a collaborative report published by GCOA and Alzheimer’s Disease International (ADI) in 2017. It analyzed the readiness of different countries to integrate innovative solutions for dementia treatment, prevention and care into their healthcare and policy systems. In 2017, the Index focused on the G7 countries – Canada, France, Germany, Italy, Japan, and the United Kingdom. In 2018, the Index will expand to focus on select G20 countries – Argentina, Brazil, China, India, and Saudi Arabia. The 2018 edition of the Index will be released at ADI’s annual conference in Chicago this July.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging. 

Ignoring the ‘Silver Economy’ May Be Getting Costly for Brands

In an ad for Airbnb that premiered earlier this year, a couple checks into a cozy Spanish villa. To the tune of Jay-Z's cover of "Me and My Girlfriend," the ad shows the pair settling into their rental and setting their collective dial to chill. They play ping-pong, sip some wine, and get ready for a night on the town. They're also in their 80s, celebrating their 57th wedding anniversary. In no way does the ad characterize the couple as elderly or portray them as needing special aid or services — they are just active people who happen to be old. It's a rare example of ads featuring a realistic depiction of aging.

Health Equity Promise and That Innovation Thing

President Biden has pledged his administration to defeat cancer, Alzheimer’s, and other diseases that target America’s aging population. To achieve these lofty goals, bold words must be backed up by bold actions.

Roundtable Report Highlights Importance of Immunizing Canada’s Caregivers Against Influenza, Identifying Challenges and Opportunities to Protect This Critical Group

The Global Coalition on Aging (GCOA) today released a report summarizing key insights from an expert roundtable on vaccinating Canada’s caregivers against influenza. The roundtable, held virtually, brought together leading Canadian health policy experts, family caregivers, patient advocacy groups, aging experts, and other thought leaders to discuss challenges and strategies to reach this critically important yet hard-to-reach group.